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Abstract DeWciencies in MHC class I antigen presenta-
tion are a common feature of tumors and allows escape
from cytotoxic T lymphocyte (CTL)-mediated killing. It is
crucial to take this capacity of tumors into account for the
development of T-cell-based immunotherapy, as it may
strongly impair their eVectiveness. A variety of escape
mechanisms has been described thus far, but progress in
counteracting them is poor. Here we review a novel strat-
egy to target malignancies with defects in the antigenic pro-
cessing machinery (APM). The concept is based on a
unique category of CD8+ T-cell epitopes that is associated
with impaired peptide processing, which we named TEIPP.
We characterized this alternative peptide repertoire emerg-
ing in MHC-I on tumors lacking classical antigen process-
ing due to defects in the peptide transporter TAP
(transporter associated with peptide processing). These
TEIPPs exemplify interesting parallels with the folktale
Wgure Cinderella: they are oppressed and neglected by a
stepmother (like functional TAP prevents TEIPP presenta-
tion), until the suppression is released and Cinderella/
TEIPP achieves unexpected recognition. TEIPP-speciWc CTLs
and their cognate peptide-epitopes provide a new strategy
to counteract immune evasion by APM defects and bear
potential to targeting escape variants observed in a wide
range of cancers.
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Introduction
One immune hallmark of tumors is their ability to evade
immune recognition [1]. Among others, a common way to
escape is through loss of antigen presentation by MHC
class I molecules (MHC-I) [2–6]. Defects in the intracellu-
lar processing pathway are often the underlying mechanism
of the MHC-I downregulation, e.g. TAP impairment is
observed from 10 to 74%, varying with tumor types [2, 3, 6,
7]. Interestingly, MHC-I downregulation has been associ-
ated with progressive disease and is very frequent in metas-
tases of cervical carcinoma, breast cancer, melanoma and
Ewing sarcoma [2, 8, 9]. Moreover, several studies found a
clinical correlation between MHC-I expression and
enhanced survival in diVerent malignancies as cervical can-
cer and HNSCC [6, 10–12]. Two recent case reports show a
strong relation between MHC-I expression on metastatic
melanoma lesions and progression of these individual
lesions during immunotherapy with IFN- [ 13,  14]. All
regressing lesions maintained MHC-I surface expression,
whereas progressing metastases were characterized by low
levels of MHC-I.
The underlying mechanisms of MHC-I downregulation
include loss of genes encoding MHC class I heavy chain
and  2-microglobulin (2m) as in loss-of-heterozygosity
(LOH), decreased transcription of MHC-I locus products
and defects in components of the antigen-processing
machinery (APM) comprising peptide transporter TAP,
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tapasin and proteasome subunits [4]. These diVerent molec-
ular mechanisms were recently classiWed as “hard” and
“soft” defects, referring to irreversible or reversible origin,
respectively, by gene-regulators or cytokines as IFN- [5].
Hard defects in this context are structural changes, as LOH,
mutations and deletions in antigen presentation involved
genes, mainly located on chromosomes 5 and 16, and in the
interferon signal transduction pathway [6, 15]. Downregula-
tion at transcriptional level and hypermethylation of MHC-I
genes as well as oncogene activation represent restorable
regulatory defects and are deWned as soft defects [5].
These studies on MHC-I defects in cancer support the
assumption that down modulation of MHC-I is a result of
genetic instability and natural selection by immune pres-
sure of naturally occurring or therapy-induced CTL-medi-
ated killing [3]. So, MHC-I loss variants may arise due
to immunological “sculpting” of early tumors enabling
these variants to escape immunosurveillance during tumor
progression [3].
Discovery of a novel CTL speciWcity combating immune 
escape variants
Conventional anti-tumor CTLs recognize tumor-speciWc
(TSA) or tumor-associated antigens (TAA) presented by
MHC-I molecules on the surface of tumor cells. Upon loss
of antigen presentation, tumor cells become invisible for
recognition by these CTLs and therefore turn resistant to
CTL-mediated killing [16]. Since impairment of TAP leads
to a limited availability of all peptide precursors in the ER,
this dysfunction impacts on the total MHC-I surface levels
leading to general impairment of recognition and elimina-
tion by anti-tumor CTLs [17].
During the search for approaches to counteract immune
escape via this route, the group of Dr. Klas Kärre discov-
ered a CD8+ T-cell subset that selectively targets TAP-deW-
cient cells [18]. This T-cell population was raised in mice
after immunization with B7.1-expressing TAP-deWcient
RMA-S lymphoma cells. In further investigations of this
phenomenon, we characterized a unique category of CTLs
that exclusively recognizes tumor cells with defects in their
APM, but not cells with proWcient APM [18–26] (Fig. 1).
Recognition depended on the 2m light chain and residual
MHC-I molecules on the tumor cells [19]. Restoration of
TAP function by gene transfer of TAP subunits or by IFN-
treatment signiWcantly decreased recognition of target cells
by these CTLs. Conversely, inhibition of TAP in dendritic
cells (DCs) by the varicellovirus-encoded evasion protein
UL49.5, which mediates degradation of mouse and human
TAP proteins [27], induced recognition of these cells by the
novel CTL category [20,  25]. Furthermore, reactivity of
these CTLs was clearly T-cell receptor dependent and their
phenotype was indistinguishable from that of conventional
CD8+ CTLs [19]. These Wndings implied that speciWcity
of the novel CTL category is based on MHC-I/peptide
complexes that are exclusively presented by processing
deWcient cells. This alternative peptide repertoire emerges
due to their APM defects we therefore named the target
structures “T-cell epitopes associated with impaired peptide
Fig. 1 Schematic diagram of 
TEIPP-speciWc CTL. Tumor 
cells with defects in the antigen-
processing machinery are recog-
nized by TEIPP-speciWc CTL, 
but not tumors with intact pro-
cessing. TEIPP antigens in 
mouse models are presented by 
classical MHC-I (upper part) as 
well as the non-classical MHC-I 
Qa-1 molecule (lower part). 
Qa-1-restricted TEIPP CTL rec-
ognize TEIPP peptides on cells 
with TAP-defects and on cells 
that lost classical MHC-I heavy 
chains
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processing” (TEIPP) [19] (Fig. 1). As TEIPP-speciWc-
CTLs do not recognize processing-proWcient cells, these
alternative peptides act as immunogenic neoantigens. Pep-
tide elution studies combined with mass spectrometry and
synthetic peptide libraries enabled the molecular identiWca-
tion of the Wrst mouse TEIPP [19]. The peptide recognized
by this Wrst CTL clone was not derived from a tumor anti-
gen as such, but from the housekeeping protein TRAM-pro-
tein homolog 4 (Trh4 or CerS5) [19]. The epitope was
located at the very C-terminus of Trh4, which is an ER
membrane spanning fatty acid regulator [28]. Since this
protein is ubiquitously expressed, it is logical that every
tumor type harboring an APM defect was recognized by
this CTL [19]. This implies that TEIPP antigens constitute
a novel category of CTL epitopes presented by a broad
range of tumors with APM defects.
Why are TEIPP peptides not presented on normal 
cells?
Since the peptides recognized by TEIPP-speciWc CTLs are
derived from housekeeping proteins, the question arises
why TEIPPs are not presented by processing-proWcient
cells. Interestingly, TAP-positive tumor cells can be ren-
dered sensitive to TEIPP-speciWc CTL after treatment with
proteasome inhibitors as, e.g. lactacystein or by deWciency
of other APM components as, e.g. tapasin [19]. These Wnd-
ings suggest that TEIPP peptides are present within pro-
cessing intact cells, but are not presented by their surface
MHC-I. Moreover, TEIPPs are presented in a TAP-inde-
pendent manner, although the exact processing pathway
and involved enzymes in their liberation still needs to be
unraveled. Several alternative processing pathways come
into consideration, including signal peptidases, Golgi pepti-
dases as e.g. furin and ER-resident endoproteases which are
responsible for cleavage of C-termini [29, 30]. However,
how the ligands of the two latter TAP-independent path-
ways gain access to compartments where MHC-I molecule
loading occurs remain elusive.
Recently, we further investigated the fact that the
described alternative peptide repertoire does not arise on
the cell surface under processing-proWcient conditions [25].
We showed that the Trh4 peptide is a stably binding peptide
and enhancing availability of MHC-I molecules did not
induce TEIPP presentation on the cell surface, indicating
that this TEIPP epitope behaves like a normal antigen as
such [25]. However, presentation of the Trh4 peptide could
be induced by overexpressing Trh4 in processing-proWcient
cells [25]. Interestingly, increasing recognition by the
TEIPP-speciWc CTL clone correlated with fold of overex-
pression in target cells. These Wndings argue against the
hypotheses that binding aYnity of TEIPP peptides might be
lower than conventional ones and therefore looses competi-
tion with high aYnity peptides in the ER, but rather, TEIPP
peptides are underrepresented in the ER and under normal
conditions a vast excess of TAP-pumped competing pep-
tides is present in the ER and prevents TEIPP loading to
MHC-I (Fig. 2). Apparently, peptides from alternative pro-
cessing routes only get the chance to be loaded when TAP
is not in optima forma. In other words, TAP behaves like a
strong barrier for alternative peptides, like TEIPP.
Interestingly, thymus epithelial cells from wildtype
mice, in contrast to those from TAP-knockout mice, were
not recognized by the TEIPP-speciWc CTL clone, albeit the
antigen is present in all thymic subpopulations [25]. This
Wnding is in line with the main characteristic of TEIPPs,
namely the exclusive emergence on processing deWcient
cells. As a consequence, TEIPP-speciWc T cells are thought
Fig. 2 Schematic illustration to explain why TEIPP peptides fail to be
presented by processing-proWcient cells. We hypothesize that TEIPP
peptides are underrepresented in the ER and lose competition with the
vast excess of TAP-pumped peptides under normal conditions. Under
TAP-deWciency, those peptides are not transported to the ER and
TEIPP peptides get the chance to be presented instead. Binding aYn-
ity and stability of the Trh4 epitope with its MHC-I seem suYcient
[25]. Note that the exact processing pathway and loading compartment
of Trh4 is still unknown
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to prevent negative selection in the thymus in normal mice.
Furthermore, they are likely to be highly aYne for TEIPPs,
unlike other T cells recognizing tumor antigens, which are
curtailed by the expression in thymus epithelial cells.
TEIPPs are presented by classical and non-classical 
MHC-I molecules
The Wrst molecular deWned TEIPP is derived from Trh4 and
is presented by the classical MHC-I molecule H2-Db. How-
ever, several other TEIPP-speciWc T cells have been iso-
lated and were found to be restricted to the non-classical
MHC molecule Qa-1 [19, 21, 26] (Fig. 1). Qa-1, the murine
equivalent of human HLA-E, is a virtually non-polymor-
phic MHC class Ib molecule playing an important role in
regulating NK cell reactivity. Qa-1 is predominantly Wlled
with “Qa-1 determinant modiWer (Qdm)” peptides, and this
complex serves as the ligand for CD94/NKG2A inhibitory
receptors expressed by a large fraction of natural killer cells
[23, 31–33]. With this receptor, natural killer cells check
the integrity of the self-MHC-I on potential target cells.
The Qdm peptide is derived from the leader sequences of
classical MHC class Ia molecules H-2D and H-2L [34].
Peptide elution studies of Qa-1 in processing-proWcient
cells showed that up to 70% of the presented peptides are
Qdm peptides [21,  35]. Importantly, Qdm processing
strictly depends on TAP function, which transports the pro-
teasome-trimmed leader peptides into the ER [36]. Thus,
absence of the predominant ligand Qdm in TAP-impaired
conditions leads to the presentation of a replacing peptide
repertoire [21]. The absence of Qdm occurred on TAP-deW-
cient tumor cells, but also on cells that lost expression of
classical MHC-I heavy chains, which encode Qdm. Qa-1
restricted TEIPP CTL responded to both types of defects
(Fig. 1). This implies that human tumors with processing
defects as well as tumors with HLA-Ia loss, for instance via
LOH, can be targeted by these CTLs. However, functional
2m molecules are still strictly required for surface expres-
sion of those epitopes. We found a surprisingly diverse
peptide repertoire of more than 100 diVerent peptides in
Qa-1 on TAP-deWcient cells [21]. The peptides originated
from housekeeping proteins within the cell and some of
them constituted neoantigens according to the TEIPP con-
cept with the ability to give rise to CD8+ T-cell responses.
The existence of Qa-1 and HLA-E-restricted CD8+ T cells
was shown before, and they recognized peptides derived
from cellular stress-related heat shock proteins and intracel-
lular pathogens [23,  37–39]. These data support the
assumption of a role of these MHC class Ib molecules in
both innate and adaptive immune responses [40]. Interest-
ingly, TEIPP-speciWc Qa-1-restricted CTL clones recog-
nized TAP-deWcient tumors from diVerent MHC haplotype
backgrounds [21] by virtue of the conserved nature of
Qa-1/HLA-E. Therefore, Qa-1/HLA-E presented TEIPP
antigens fulWll quite some requirements of ideal tumor anti-
gens.
TEIPP antigens do exist in humans
Alternative peptide repertoires presented by TAP-deWcient
human cells have been described and provided Wrst indica-
tions for availability of TEIPP candidates among them [41–
43]. Further evidence for existence of TEIPPs in human
was shown by the experiments with TAP inhibitors derived
from herpesviruses. It is a common strategy of viruses, in
particular of the herpes family, to target APM components
in order to circumvent immunosurveillance by CTL [44].
Examples of viral proteins targeting TAP are ICP47 (HSV),
US6 (HCMV), BNLF2a (EBV), and UL49.5 (varicellovi-
ruses). By introducing UL49.5 via gene transfer in human
DCs, TAP activity was successfully inhibited [22]. These
human TAP-impaired DCs were used as stimulators for
autologous T-cell cultures and the resulting CTLs displayed
selective killing of TAP-impaired target cells. These Wnd-
ings formally demonstrate the existence of TEIPP-speciWc
CTLs in the human CD8+ T-cell pool which are likely to
come with a relative high frequency among the precursor
population as they are readily detectable on bulk level [22].
Furthermore, in silico predictions for immunogenic TAP-
independent HLA-Ia binding peptides and HLA-E peptide
elution studies with TAP-deWcient cells provided a multi-
plicity of potential TEIPP candidates. The most immuno-
genic peptides among them will be deWned in current
investigations.
Interestingly, a CTL epitope derived from the precursor
signal peptide of preprocalcitonin (ppCT) was recently
shown to be processed in a TAP-independent manner [45].
The described HLA-A2-restricted CTL clone was isolated
from a lung cancer patient and recognizes autologous
lung carcinoma cells in which overexpression of ppCT
transcripts was detected. Recent data of the group of
Dr. Mami-Chouaib show that downregulation of TAP is
required to allow presentation of this ppCT peptide [49].
Therefore, we consider this CTL epitope, derived from a
primary human tumor, as the Wrst molecular deWned
human TEIPP.
Potential applications of TEIPP peptides 
in immunotherapy
Can TEIPP antigens be exploited like normal tumor anti-
gens? We belief they can. In mouse models, we showed
that adoptively transferred TEIPP-speciWc CTLs was ableCancer Immunol Immunother (2012) 61:119–125 123
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to eradicate TAP-deWcient tumor cell in vivo and control
the outgrowth of a lethal dose [19]. In addition, peptide
vaccination studies with the Wrst molecular deWned TEIPP-
speciWc CTL epitope induced a protective antitumor CTL
response and subsequently prevented outgrowth of the
same TAP-deWcient tumor [19]. Furthermore, immuniza-
tion with TAP-deWcient DCs mediated protection to TAP-
deWcient tumor challenge [20]. This DC-based cellular
vaccine is characterized by presentation of a variety of
endogenous TEIPP antigens by MHC-I molecules. Impor-
tantly, in this vaccination strategy, TEIPP antigens do not
require to be molecularly identiWed. Finally, others demon-
strated that tumor cell vaccines consisting of TAP-impaired
tumor cell lines might also induce immune protection, pro-
vided that enough co-stimulation on the tumor cell vaccine
is at hand [46, 47]. The applicability of this variety of thera-
peutic immune interventions shows that TEIPPs can be
exploited alike conventional tumor antigens, despite their
unconventional character.
We anticipate that TEIPP antigens constitute a novel cat-
egory of tumor antigens that might contribute to the
eYcacy of T-cell-based immunotherapy in the future with
the aim to prevent outgrowth of AMP-deWcient tumor vari-
ants [24, 48]. Tumors with “hard” defects in the APM are
likely targets, but also therapy for tumors with “soft”
defects might beneWt from TEIPP-speciWc CTL, as these
tumors might ignite an initial supply of IFN- leading to the
restoration of “soft” defects. Clearly, TEIPP antigens might
complement currently available tumor antigens in order to
improve the eYcacy of cancer vaccines.
Cinderella as a prototype
Daydreaming about TEIPP antigens, the folktale story of
Cinderella came to our mind (Fig. 3). The fairy tale Wgure
of Cinderella is unjustly oppressed by her stepmother, just
like TEIPP antigens are suppressed by a functional TAP.
However, her beauty is then openly revealed and she
achieves unexpected recognition by Prince Charming at the
ball. Once her oppression and neglect are taken away, her
full beauty is displayed. We hope that, in parallel, TEIPP
antigens will comparably contribute to eVective immuno-
therapy for cancer.
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